Correlation Between Inhibikase Therapeutics and Sonnet Biotherapeutics
Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Sonnet Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Sonnet Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibikase Therapeutics and Sonnet Biotherapeutics Holdings, you can compare the effects of market volatilities on Inhibikase Therapeutics and Sonnet Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Sonnet Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Sonnet Biotherapeutics.
Diversification Opportunities for Inhibikase Therapeutics and Sonnet Biotherapeutics
-0.68 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Inhibikase and Sonnet is -0.68. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Sonnet Biotherapeutics Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sonnet Biotherapeutics and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Sonnet Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sonnet Biotherapeutics has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Sonnet Biotherapeutics go up and down completely randomly.
Pair Corralation between Inhibikase Therapeutics and Sonnet Biotherapeutics
Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 1.07 times more return on investment than Sonnet Biotherapeutics. However, Inhibikase Therapeutics is 1.07 times more volatile than Sonnet Biotherapeutics Holdings. It trades about 0.02 of its potential returns per unit of risk. Sonnet Biotherapeutics Holdings is currently generating about -0.12 per unit of risk. If you would invest 412.00 in Inhibikase Therapeutics on September 2, 2024 and sell it today you would lose (120.00) from holding Inhibikase Therapeutics or give up 29.13% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inhibikase Therapeutics vs. Sonnet Biotherapeutics Holding
Performance |
| Timeline |
| Inhibikase Therapeutics |
| Sonnet Biotherapeutics |
Inhibikase Therapeutics and Sonnet Biotherapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inhibikase Therapeutics and Sonnet Biotherapeutics
The main advantage of trading using opposite Inhibikase Therapeutics and Sonnet Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Sonnet Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonnet Biotherapeutics will offset losses from the drop in Sonnet Biotherapeutics' long position.| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
| Sonnet Biotherapeutics vs. ZyVersa Therapeutics | Sonnet Biotherapeutics vs. Allarity Therapeutics | Sonnet Biotherapeutics vs. Immix Biopharma | Sonnet Biotherapeutics vs. Cns Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Complementary Tools
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |